Drug Research, Table of Contents Drug Res (Stuttg) 2018; 68(S 01): S8-S9DOI: 10.1055/a-0733-0783 Symposium der Paul-Martini-Stiftung Georg Thieme Verlag KG Stuttgart · New YorkLangzeitpharmakovigilanz bei Kinderarzneimitteln Authors Author Affiliations Peter-Andreas Löschmann 1 Pfizer Pharma GmbH, Berlin Gerd Horneff 2 Asklepios Klinik St. Augustin GmbH Recommend Article Abstract Full Text References Literatur 1 Strom BL. Study designs available for pharmacoepidemiology. In: Strom BL. ed. Pharmacoepidemiology. 3rd ed.. Hoboken, NJ: John Wiley & Sons; 2000: 20 2 Wilton P, Mattsson AF, Darendeliler F. Growth hormone treatment in children is not associated with an increase in the incidence of cancer: experience from KIGS (Pfizer International Growth Database). J Pediatr 2010; 157: 265-270 3 Ranke MB, Lindberg A. Predicting growth in response to growth hormone treatment. Growth Horm IGF Res 2009; 19: 1-11 4 Ranke MB, Lindberg A. KIGS International Board. Observed and predicted growth responses in prepubertal children with growth disorders: guidance of growth hormone treatment by empirical variables. J Clin Endocrinol Metab 2010; 95: 1229-1237 5 Europäische Union. Pharmakovigilanzrichtlinie des Europäischen Parlaments und des Rates (2010/84/EU). Online: https://ec.europa.eu/health//sites/health/files/files/eudralex/vol-1/dir_2010_84/dir_2010_84_de.pdf http:// Stand: 20.09.2018 6 Woo P, Wedderburn LR. Juvenile chronic arthritis. Lancet 1998; 351: 969-973 7 Petty RE, Southwood TR, Baum J. et al. Revision of the proposed criteria for juvenile idiopathic arthritis: Durban 1997. J Rheumatol 1998; 25: 1991-1994 8 Nordal E, Zak M, Aalto K. et al. Nordic Study Group of Pediatric Rheumatology. Ongoing disease activity and changing categories in a long-term nordic cohort study of juvenile idiopathic arthritis. Arthritis Rheum 2011; 63: 2809-2818 9 Pfizer. Fachinformation Enbrel 10 mg für Kinder und Jugendliche. Im Internet: https://www.pfizer.de/fileadmin/produktdatenbank/pdf/013264_freigabe.pdf Stand: 20.09.2018 10 Horneff G, Schmeling H, Biedermann T. et al. for the Paediatric Rheumatology Collaborative Group. The German etanercept registry for treatment of juvenile idiopathic arthritis. Ann Rheum Dis 2004; 63: 1638-1644 11 Horneff G. Biologic-associated infections in pediatric rheumatology. Curr Rheumatol Rep 2015; 17: 66 12 Becker I, Horneff G. Risk of serious infection in juvenile idiopathic arthritis patients associated with TNF-inhibitors and disease activity in the German BIKER registry. Arthritis Care Res (Hoboken) 2016; 13 Foeldvari I, Becker I, Horneff G. Uveitis Events During Adalimumab, Etanercept, and Methotrexate Therapy in Juvenile Idiopathic Arthritis: Data From the Biologics in Pediatric Rheumatology Registry. Arthritis Care Res (Hoboken) 2015; 67: 1529-1535 14 Horneff G, Foeldvari I, Minden K. et al. Report on malignancies in the German juvenile idiopathic arthritis registry. Rheumatology (Oxford) 2011; 50: 230-236 15 Horneff G, Klein A, Oommen PT. et al. Update on malignancies in children with juvenile idiopathic arthritis in the German BIKER Registry. Clin Exp Rheumatol 2016; 34: 1113-1120 16 Klotsche J, Raab A, Niewerth M. et al. Outcome and trends in treatment of systemic juvenile idiopathic arthritis in the German National Pediatric Rheumatological Database from 2000 to 2013. Arthritis Rheumatol 2016; 17 Windschall D, Horneff G. Safety and efficacy of etanercept and adalimumab in children aged 2 to 4 years with juvenile idiopathic arthritis. Clin Rheumatol 2016; 35: 2925-2931 18 Niewerth M, Minden K, Klotsche J. et al. [Therapy of juvenile idiopathic arthritis in early adulthood with biologics: transition from pediatric to adult care]. Z Rheumatol 2014; 73: 532-540
